The Effect of Atropine on Myopic Progression in Children.

Purpose: To examine the effects of atropine therapy on myopic progression in myopic children. Methods: Fifty myopic patients, aged from 7 to 14 years and less than -5 diopters, visited our clinic for correction of refractive error from August 2001, and were followed up for at least 1 year. Of these 50 patients, the atropine therapy group was 23 and the control group was 27. Right eye cycloplegic refraction and axial length changes of the two groups were compared and analyzed. Results: There was a mean increase of myopia of 0.250.43 D/yr in the atropine therapy group and of 0.830.37 D/yr in the control group (P=0.000). There was a mean increase of axial length of 0.120.19 mm/yr in the atropine therapy group and 0.390.21 mm/yr in the control group (P=0.000). In refraction and axial length changes according to age, there was no statistically significant difference within the group, aged from 7 to 9 years. However, there was a statistically significant difference within the group, aged from 10 to 14 years. In refraction and axial length changes according to myopic grade, there were a statistically significant differences between the groups. Conclusions: Atropine therapy is effective in slowing the myopic progression in myopic children with refractive error less than -5 diopters.